- NCX 470 Phase 3 trials in glaucoma on track for top-line results in Q2 2022 (Mont Blanc) and Q4 2022 (Denali)
- NCX 4251 Mississippi Phase 2b trial in blepharitis on track for top-line results in Q4 2021
- U.S. prescriptions for VYZULTA® in Q1 2021 increased by 10.6% over Q1 2020, and for ZERVIATE® by 29.1% over Q4 2020
- Q1 2021 net revenue of €0.6 million and cash of €42.0 million at March 31, 2021
April 19, 2021 – release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and financial highlights for Q1 2021 for Nicox SA and its subsidiaries (the “Nicox Group”), and updated key expected value-inflection milestones.
Key Expected Milestones
- NCX 470 Phase 3 program in glaucoma: Nicox’s lead clinical product candidate, NCX 470, is a novel nitric oxide (NO)-donating prostaglandin analog currently in two multi-regional Phase 3 trials for the evaluation of the safety and efficacy of NCX 470 ophthalmic solution, 0.1%, against latanoprost ophthalmic solution, 0.005%, for lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Top-line results are currently expected in Q2 2022 for Mont Blanc and in Q4 2022 for Denali.
- NCX 4251 Phase 2b trial, Mississippi in blepharitis: NCX 4251 is a novel patented ophthalmic suspens
|
